Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 13066-13068 [2014-04958]

Download as PDF mstockstill on DSK4VPTVN1PROD with NOTICES 13066 Federal Register / Vol. 79, No. 45 / Friday, March 7, 2014 / Notices information, when available, will be posted on the BSC meeting Web site (https://ntp.niehs.nih.gov/go/165) or may be requested in hardcopy from the Designated Federal Officer for the BSC. Following the meeting, summary minutes will be prepared and made available on the BSC meeting Web site. The public may attend the meeting in person or view the webcast of the open sessions, which begin at 2 p.m. on April 17, 2014. Registration is required to view the webcast; the URL for the webcast will be provided in the email confirming registration. Individuals who plan to provide oral comments (see below) are encouraged to preregister online at the BSC meeting Web site (https://ntp.niehs.nih.gov/go/165) by April 9, 2014, to facilitate planning for the meeting. Individuals interested in this meeting are encouraged to access the Web site to stay abreast of the most current information regarding the meeting. Visitor and security information for those attending inperson is available at niehs.nih.gov/ about/visiting/index.cfm. Individuals with disabilities who need accommodation to participate in this event should contact Dr. White at phone: (919) 541–9834 or email: whiteld@niehs.nih.gov. TTY users should contact the Federal TTY Relay Service at 800–877–8339. Requests should be made at least five business days in advance of the event. Request for Comments: Written comments submitted in response to this notice should be received by April 2, 2014. Comments will be posted on the BSC meeting Web site and persons submitting them will be identified by their name and affiliation and/or sponsoring organization, if applicable. Persons submitting written comments should include their name, affiliation (if applicable), phone, email, and sponsoring organization (if any) with the document. Time is allotted during the open portion of the meeting for the public to present oral comments to the BSC on the agenda topics. Public comments can be presented in-person at the meeting at NIEHS or by teleconference line. There are 50 lines for this call; availability is on a first-come, first-served basis. The available lines will be open from 2:00 p.m. on April 17 and from 8:30 a.m. on April 18 until adjournment, although the BSC will receive public comments only during the formal public comment periods, which are indicated on the preliminary agenda. Each organization is allowed one time slot per agenda topic. Each speaker is allotted at least 7 minutes, which if time permits, may be extended to 10 minutes at the discretion VerDate Mar<15>2010 18:39 Mar 06, 2014 Jkt 232001 of the BSC chair. Persons wishing to present oral comments should register on the BSC meeting Web site by April 9, 2014, indicate whether they will present comments in-person or via the teleconference line, and indicate the topic(s) on which they plan to comment. The access number for the teleconference line will be provided to registrants by email prior to the meeting. On-site registration for oral comments will also be available on the meeting day, although time allowed for presentation by these registrants may be less than that for pre-registered speakers and will be determined by the number of persons who register at the meeting. Persons registering to make oral comments are asked to send a copy of their statement and/or PowerPoint slides to the Designated Federal Officer by April 9, 2014. Written statements can supplement and may expand upon the oral presentation. If registering on-site and reading from written text, please bring 40 copies of the statement for distribution to the BSC and NTP staff and to supplement the record. Background Information on the BSC: The BSC is a technical advisory body comprised of scientists from the public and private sectors that provides primary scientific oversight to the NTP. Specifically, the BSC advises the NTP on matters of scientific program content, both present and future, and conducts periodic review of the program for the purpose of determining and advising on the scientific merit of its activities and their overall scientific quality. Its members are selected from recognized authorities knowledgeable in fields such as toxicology, pharmacology, pathology, biochemistry, epidemiology, risk assessment, carcinogenesis, mutagenesis, molecular biology, behavioral toxicology, neurotoxicology, immunotoxicology, reproductive toxicology or teratology, and biostatistics. Members serve overlapping terms of up to four years. The BSC usually meets biannually. The authority for the BSC is provided by 42 U.S.C. 217a, section 222 of the Public Health Service Act (PHS), as amended. The BSC is governed by the provisions of the Federal Advisory Committee Act, as amended (5 U.S.C. app.), which sets forth standards for the formation and use of advisory committees. Dated: February 28, 2014. John R. Bucher, Associate Director, National Toxicology Program. [FR Doc. 2014–04942 Filed 3–6–14; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. AGENCY: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809). A notice listing all currently HHScertified laboratories and IITFs is published in the Federal Register during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at https:// www.workplace.samhsa.gov. FOR FURTHER INFORMATION CONTACT: Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 7–1051, One Choke Cherry Road, Rockville, Maryland 20857; 240–276– 2600 (voice), 240–276–2610 (fax). SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The ‘‘Mandatory Guidelines for Federal Workplace Drug Testing Programs,’’ as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and SUMMARY: E:\FR\FM\07MRN1.SGM 07MRN1 Federal Register / Vol. 79, No. 45 / Friday, March 7, 2014 / Notices specimen validity tests on urine specimens for federal agencies. To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards. In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHScertified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens: HHS-Certified Instrumented Initial Testing Facilities Gamma-Dynacare Medical Laboratories, 6628 50th Street NW., Edmonton, AB Canada T6B 2N7, 780–784–1190. mstockstill on DSK4VPTVN1PROD with NOTICES HHS-Certified Laboratories ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328– 7840/800–877–7016 (Formerly: Bayshore Clinical Laboratory). ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585–429–2264. Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615– 255–2400, (Formerly: Aegis Sciences Corporation, Aegis Analytical Laboratories, Inc., Aegis Analytical Laboratories). Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504–361–8989/ 800–433–3823, (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.). Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 804–378–9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.). Baptist Medical Center-Toxicology Laboratory, 11401 I–30, Little Rock, AR 72209–7056, 501–202–2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center). Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215–2802, 800– 445–6917. VerDate Mar<15>2010 18:39 Mar 06, 2014 Jkt 232001 Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229–671– 2281. DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800– 235–4890. ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662– 236–2609. Fortes Laboratories, Inc., 25749 SW Canyon Creek Road, Suite 600, Wilsonville, OR 97070, 503–486– 1023. Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519– 679–1630. Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288/ 800–800–2387. Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526–2400/800–437–4986, (Formerly: Roche Biomedical Laboratories, Inc.). Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919–572–6900/800–833–3984, (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group). Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866–827–8042/ 800–233–6339, (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center). LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927/800–873–8845, (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.). MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 651–636–7466/800–832–3244. MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295/800–950–5295. Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612–725– 2088. National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661–322–4250/800–350–3515. One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 13067 77504, 888–747–3774, (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory). Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800–328–6942, (Formerly: Centinela Hospital Airport Toxicology Laboratory). Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509–755–8991/ 800–541–7891 x7. Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858–643– 5555. Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084, 800–729–6432, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories). Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 610–631–4600/877–642–2216, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline BioScience Laboratories). Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA 91304, 818–737–6370, (Formerly: SmithKline Beecham Clinical Laboratories). Redwood Toxicology Laboratory, 3650 Westwind Blvd., Santa Rosa, CA 95403, 707–570–4434. South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574–234–4176 x 1276. Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177, Phoenix, AZ 85040, 602–438–8507/800–279– 0027. STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington 98421, 800–442–0438. Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 573–882–1273. U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755– 5235, 301–677–7085. * The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories E:\FR\FM\07MRN1.SGM 07MRN1 13068 Federal Register / Vol. 79, No. 45 / Friday, March 7, 2014 / Notices was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do. Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 30, 2010 (75 FR 22809). After receiving DOT certification, the laboratory will be included in the monthly list of HHScertified laboratories and participate in the NLCP certification maintenance program. Center for Substance Abuse Treatment National Advisory Council. Date/Time/Type: April 2, 2014, 9:30 a.m.– 5:00 p.m. (OPEN) Place: SAMHSA Building, Sugarloaf Conference Room, 1 Choke Cherry, Rockville, MD 20857. Contact: Cynthia Graham, M.S., Designated Federal Official, SAMHSA/CSAT National Advisory Council, 1 Choke Cherry Road, Room 5–1035, Rockville, MD 20857, Telephone: (240) 276–1692, FAX: (240) 276– 1690, Email: cynthia.graham@ samhsa.hhs.gov. Summer King, Statistician. Substance Abuse and Mental Health Services Administration Cathy J. Friedman, Public Health Analyst, SAMHSA. [FR Doc. 2014–05004 Filed 3–6–14; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2014–04958 Filed 3–6–14; 8:45 am] Matthew J. Aumen. A transcript of the open portion of the meeting will also be available on the SAMHSA Web site after the meeting. Committee Name: Substance Abuse and Mental Health Services, Administration, Center for Substance Abuse Prevention, National Advisory Council. Date/Time/Type: April 2, 2014, from 10:00 a.m. to 4:00 p.m. EDT: (OPEN) Place: SAMHSA, 1 Choke Cherry Road, Rock Creek Conference Room (lobby level), Rockville, MD 20857. Contact: Matthew J. Aumen, Designated Federal Officer, SAMHSA CSAP NAC, 1 Choke Cherry Road, Rockville, MD 20857, Telephone: 240–276–2419, Fax: 240–276– 2430, Email: matthew.aumen@ samhsa.hhs.gov. Cathy J. Friedman, Public Health Analyst, SAMHSA. [FR Doc. 2014–05003 Filed 3–6–14; 8:45 am] BILLING CODE 4162–20–P BILLING CODE 4160–20–P Center for Substance Abuse Prevention; Notice of Meeting DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to Public Law 92–463, notice is hereby given for the meeting of the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention National Advisory Council (CSAP NAC) on April 2, 2014. The Council was established to advise the Secretary, Department of Health and Human Services (HHS); the Administrator, SAMHSA; and Center Director, CSAP concerning matters relating to the activities carried out by and through the Center and the policies respecting such activities. The meeting will be open to the public and include discussion of prevention in the context of primary care, SAMHSA’s Strategic Initiative on the Prevention of Substance Abuse and Mental Illness, communications, and CSAP program and budget developments. To attend the public portion of the meeting onsite, submit written or brief oral comments, request special accommodations for persons with disabilities, or participate via Webcast, please register at the SAMHSA Committees’ Web site, https:// nac.samhsa.gov/Registration/ meetingsRegistration.aspx, or communicate with the CSAP Council’s Designated Federal Officer (see contact information below). Substantive program information, a summary of the meeting, and a roster of committee members may be obtained either by accessing the SAMHSA Committee’s Web site after the meeting, https://nac.samhsa.gov/, or by contacting Substance Abuse and Mental Health Services Administration Substance Abuse and Mental Health Services Administration mstockstill on DSK4VPTVN1PROD with NOTICES Notice of Meeting Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Treatment (CSAT) National Advisory Council will meet April 2, 2014, 9:30 a.m.–5:00 p.m. The meeting is open to the public and will include a discussion of the Center’s current administrative, legislative, and program developments. Public comments are welcome. To attend onsite, or request special accommodations for persons with disabilities, please register at SAMHSA Committees’ Web site, https://nac.samhsa.gov/ Registration/meetingsRegistration.aspx or contact the Council’s Designated Federal Officer, Ms. Cynthia Graham, (see contact information below). Individuals interested in making oral comments or obtaining the meeting number and passcode are encouraged to notify Ms.Graham, on or before March 24. Substantive program information, a summary of the meeting and a roster of Council members may be obtained 30 days following the meeting by accessing the SAMHSA Committee Web site at https://nac.samhsa.gov/CSATcouncil/ index.aspx or contacting Ms. Graham. Committee Name: Substance Abuse and Mental Health Services Administration, VerDate Mar<15>2010 18:39 Mar 06, 2014 Jkt 232001 PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 National Advisory Council; Notice of Meeting Pursuant to Public Law 92–463, notice is hereby given of a meeting of the Substance Abuse and Mental Health Services Administration’s (SAMHSA) National Advisory Council (NAC) on April 4, 2014. The meeting will include discussions of SAMHSA’s Leadership Role in an Integrated Health Environment, SAMHSA and Military Families, and SAMHSA’s Communication Strategy. The meeting is open to the public and will be held at the SAMHSA building, 1 Choke Cherry Road, Rockville, MD 20857 in the Sugarloaf Conference Room. Attendance by the public will be limited to space available. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions should be forwarded to the contact person on or before one week prior to the meeting. Oral presentations from the public will be scheduled at the conclusion of the meeting. Individuals interested in making oral presentations are encouraged to notify the contact on or before one week prior to the meeting. Five minutes will be allotted for each presentation. The meeting may be accessed via teleconference. The meeting will be available via teleconference at 888–390– 0854, Participant passcode: SAMHSA. To attend on site, obtain the call-in number and access code, submit written E:\FR\FM\07MRN1.SGM 07MRN1

Agencies

[Federal Register Volume 79, Number 45 (Friday, March 7, 2014)]
[Notices]
[Pages 13066-13068]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-04958]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Current List of HHS-Certified Laboratories and Instrumented 
Initial Testing Facilities Which Meet Minimum Standards To Engage in 
Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services (HHS) notifies 
federal agencies of the laboratories and Instrumented Initial Testing 
Facilities (IITF) currently certified to meet the standards of the 
Mandatory Guidelines for Federal Workplace Drug Testing Programs 
(Mandatory Guidelines). The Mandatory Guidelines were first published 
in the Federal Register on April 11, 1988 (53 FR 11970), and 
subsequently revised in the Federal Register on June 9, 1994 (59 FR 
29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); 
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and 
on April 30, 2010 (75 FR 22809).
    A notice listing all currently HHS-certified laboratories and IITFs 
is published in the Federal Register during the first week of each 
month. If any laboratory or IITF certification is suspended or revoked, 
the laboratory or IITF will be omitted from subsequent lists until such 
time as it is restored to full certification under the Mandatory 
Guidelines.
    If any laboratory or IITF has withdrawn from the HHS National 
Laboratory Certification Program (NLCP) during the past month, it will 
be listed at the end and will be omitted from the monthly listing 
thereafter.
    This notice is also available on the Internet at https://www.workplace.samhsa.gov.

FOR FURTHER INFORMATION CONTACT: Giselle Hersh, Division of Workplace 
Programs, SAMHSA/CSAP, Room 7-1051, One Choke Cherry Road, Rockville, 
Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially 
developed in accordance with Executive Order 12564 and section 503 of 
Public Law 100-71. The ``Mandatory Guidelines for Federal Workplace 
Drug Testing Programs,'' as amended in the revisions listed above, 
requires strict standards that laboratories and IITFs must meet in 
order to conduct drug and

[[Page 13067]]

specimen validity tests on urine specimens for federal agencies.
    To become certified, an applicant laboratory or IITF must undergo 
three rounds of performance testing plus an on-site inspection. To 
maintain that certification, a laboratory or IITF must participate in a 
quarterly performance testing program plus undergo periodic, on-site 
inspections.
    Laboratories and IITFs in the applicant stage of certification are 
not to be considered as meeting the minimum requirements described in 
the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must 
have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), 
which attests that it has met minimum standards.
    In accordance with the Mandatory Guidelines dated November 25, 2008 
(73 FR 71858), the following HHS-certified laboratories and IITFs meet 
the minimum standards to conduct drug and specimen validity tests on 
urine specimens:

HHS-Certified Instrumented Initial Testing Facilities

Gamma-Dynacare Medical Laboratories, 6628 50th Street NW., Edmonton, AB 
Canada T6B 2N7, 780-784-1190.

HHS-Certified Laboratories

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-
7840/800-877-7016 (Formerly: Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 
585-429-2264.
Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 
37210, 615-255-2400, (Formerly: Aegis Sciences Corporation, Aegis 
Analytical Laboratories, Inc., Aegis Analytical Laboratories).
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823, (Formerly: Kroll Laboratory Specialists, Inc., 
Laboratory Specialists, Inc.).
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 
804-378-9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific 
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, 
Inc.).
Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little Rock, 
AR 72209-7056, 501-202-2783, (Formerly: Forensic Toxicology Laboratory 
Baptist Medical Center).
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802, 800-
445-6917.
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229-
671-2281.
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890.
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 
662-236-2609.
Fortes Laboratories, Inc., 25749 SW Canyon Creek Road, Suite 600, 
Wilsonville, OR 97070, 503-486-1023.
Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-Dynacare 
Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A 
1P4, 519-679-1630.
Laboratory Corporation of America Holdings, 7207 N. Gessner Road, 
Houston, TX 77040, 713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 
08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical 
Laboratories, Inc.).
Laboratory Corporation of America Holdings, 1904 Alexander Drive, 
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly: 
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, 
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical 
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche 
Group).
Laboratory Corporation of America Holdings, 1120 Main Street, 
Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp 
Occupational Testing Services, Inc.; MedExpress/National Laboratory 
Center).
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 
66219, 913-888-3927/800-873-8845, (Formerly: Quest Diagnostics 
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division 
of LabOne, Inc.).
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 
651-636-7466/800-832-3244.
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 
97232, 503-413-5295/800-950-5295. Minneapolis Veterans Affairs Medical 
Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, 
MN 55417, 612-725-2088.
National Toxicology Laboratories, Inc., 1100 California Ave., 
Bakersfield, CA 93304, 661-322-4250/800-350-3515.
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, 
TX 77504, 888-747-3774, (Formerly: University of Texas Medical Branch, 
Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 
91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology 
Laboratory).
Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, 
WA 99204, 509-755-8991/800-541-7891 x7.
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858-
643-5555.
Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084, 
800-729-6432, (Formerly: SmithKline Beecham Clinical Laboratories; 
SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 
610-631-4600/877-642-2216, (Formerly: SmithKline Beecham Clinical 
Laboratories; SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA 
91304, 818-737-6370, (Formerly: SmithKline Beecham Clinical 
Laboratories).
Redwood Toxicology Laboratory, 3650 Westwind Blvd., Santa Rosa, CA 
95403, 707-570-4434.
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South 
Bend, IN 46601, 574-234-4176 x 1276.
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177, 
Phoenix, AZ 85040, 602-438-8507/800-279-0027.
STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington 
98421, 800-442-0438.
Toxicology & Drug Monitoring Laboratory, University of Missouri 
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 
65203, 573-882-1273.
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., 
Fort George G. Meade, MD 20755-5235, 301-677-7085.

    * The Standards Council of Canada (SCC) voted to end its Laboratory 
Accreditation Program for Substance Abuse (LAPSA) effective May 12, 
1998. Laboratories certified through that program were accredited to 
conduct forensic urine drug testing as required by U.S. Department of 
Transportation (DOT) regulations. As of that date, the certification of 
those accredited Canadian laboratories will continue under DOT 
authority. The responsibility for conducting quarterly performance 
testing plus periodic on-site inspections of those LAPSA-accredited 
laboratories

[[Page 13068]]

was transferred to the U.S. HHS, with the HHS' NLCP contractor 
continuing to have an active role in the performance testing and 
laboratory inspection processes. Other Canadian laboratories wishing to 
be considered for the NLCP may apply directly to the NLCP contractor 
just as U.S. laboratories do.
    Upon finding a Canadian laboratory to be qualified, HHS will 
recommend that DOT certify the laboratory (Federal Register, July 16, 
1996) as meeting the minimum standards of the Mandatory Guidelines 
published in the Federal Register on April 30, 2010 (75 FR 22809). 
After receiving DOT certification, the laboratory will be included in 
the monthly list of HHS-certified laboratories and participate in the 
NLCP certification maintenance program.

Summer King,
Statistician.
[FR Doc. 2014-04958 Filed 3-6-14; 8:45 am]
BILLING CODE 4160-20-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.